Publication Name	World Journal of Hematology
Manuscript ID	29628
Country	Türkiye

Received	2016-08-23 10:05
Peer-Review Started	2016-08-24 19:13
To Make the First Decision	2016-10-20 08:29
Return for Revision	2016-10-20 15:51
Revised	2016-10-21 14:40
Second Decision	2016-12-21 08:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-01-03 15:10
Articles in Press	2017-01-03 15:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-01-09 08:45
Publish the Manuscript Online	2017-01-19 08:03

ISSN	2218-6204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Frontier
Article Title	Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience
Manuscript Source	Invited Manuscript
All Author List	Nur Soyer, Ayse Uysal, Murat Tombuloglu, Fahri Sahin, Guray Saydam and Filiz Vural
Funding Agency and Grant Number
Corresponding Author	Nur Soyer, MD, Department of Hema­tology, Ege University Medical Faculty, Ankara Blvd, Bornova, 35100 Izmir, Turkey. drakadnur@yahoo.com
Key Words	Chronic myeloid leukemia; Allogeneic stem cell transplantation; Tyrosine kinase inhibitors; Graft <i>vs</i> host disease; Survival
Core Tip	Tyrosine kinase inhibitors (TKIs) have changed the fatal outcomes of chronic myeloid leukemia (CML). Many studies showed that TKIs provided rapid response, few serious adverse event and impressive survival out-comes. Although, allogeneic stem cell transplantation (ASCT) is only curative treatment option for CML, since 1999, the numbers of ASCT have dropped. Currently, ASCT is offering for patients who are resistant or intolerant to at least one second generation TKI or for patients with blastic phase. Here, we present our center’s out-comes of ASCT for patients with CML and then, we discuss the place of ASCT in CML treatment in the TKIs era.
Publish Date	2017-01-19 08:03
Citation	Soyer N, Uysal A, Tombuloglu M, Sahin F, Saydam G, Vural F. Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience. World J Hematol 2017; 6(1): 1-10
URL	http://www.wjgnet.com/2218-6204/full/v6/i1/1.htm
DOI	http://dx.doi.org/10.5315/wjh.v6.i1.1

Full Article (PDF)	WJH-6-1.pdf
Full Article (Word)	WJH-6-1.doc
Manuscript File	29628-Review.docx
Answering Reviewers	29628-Answering reviewers.pdf
Audio Core Tip	29628-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	29628-Conflict-of-interest statement.pdf
Copyright License Agreement	29628-Copyright assignment.pdf
Peer-review Report	29628-Peer-review(s).pdf
Scientific Misconduct Check	29628-Scientific misconduct check.pdf
Scientific Editor Work List	29628-Scientific editor work list.pdf